Phathom Pharmaceuticals (PHAT) Common Equity (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Common Equity of -$344.3 million for Q2 2026, up 15.17% year-over-year from -$298.9 million in Q2 2025, and down 2.17% quarter-over-quarter from -$337.0 million in Q1 2026.
Phathom Pharmaceuticals (PHAT) Common Equity (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Common Equity for 9 consecutive years, with -$344.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Common Equity rose 15.17% year-over-year to -$344.3 million; the TTM figure through Jun 2026 stood at -$344.3 million (up 15.17% YoY), while the FY2025 annual figure was -$438.2 million, down 72.79% from the prior year.
- Common Equity slipped to -$344.3 million in Q2 2026 per PHAT's latest filing, from -$337.0 million in the prior quarter.
- Across five years, Common Equity topped out at $38.0 million in Q1 2022 and bottomed at -$438.2 million in Q4 2025.
- Historically, Common Equity has averaged -$185.7 million across 5 years, with a median of -$167.8 million in 2024.
- Annual changes were most pronounced in 2023 — Common Equity jumped 351.43% — and 2024, when it plunged 1428.57%.
- Phathom Pharmaceuticals' Common Equity stood at -$74.8 million in 2022, then increased by 2.75% to -$72.8 million in 2023, then sank by 248.52% to -$253.6 million in 2024, then tumbled by 72.79% to -$438.2 million in 2025, then grew by 21.43% to -$344.3 million in 2026.
- Business Quant data shows PHAT's Common Equity at -$344.3 million in Q2 2026, -$337.0 million in Q1 2026, and -$438.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | -344.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -344.27 Mn |
| Mar 31, 2026 | -336.96 Mn |
| Dec 31, 2025 | -438.17 Mn |
| Sep 30, 2025 | -422.53 Mn |
| Jun 30, 2025 | -405.83 Mn |
| Mar 31, 2025 | -338.38 Mn |
| Dec 31, 2024 | -253.58 Mn |
| Sep 30, 2024 | -187.11 Mn |
| Jun 30, 2024 | -233.83 Mn |
| Mar 31, 2024 | -148.50 Mn |
| Dec 31, 2023 | -72.76 Mn |
| Sep 30, 2023 | -17.77 Mn |
| Jun 30, 2023 | 17.60 Mn |
| Mar 31, 2023 | -90.20 Mn |
| Dec 31, 2022 | -74.81 Mn |
| Sep 30, 2022 | -26.42 Mn |
| Jun 30, 2022 | -7.00 Mn |
| Mar 31, 2022 | 38.04 Mn |
| Dec 31, 2021 | 72.16 Mn |
| Sep 30, 2021 | 103.48 Mn |